Georgia Champion Takes Top Honor at Prestigious International BioGENEius Challenge

Milton High School Senior  Shreya Ramesh  Achieves Global Excellence in Scientific Research

ATLANTA–( BUSINESS WIRE )–Shreya Ramesh, a Milton High School senior, from Milton, Georgia, and local winner of the Georgia BioGENEius Challenge, has taken the top prize at the fiercely competitive International BioGENEius Challenge. Shreya’s innovative work on voice recognition data and Amyotrophic Lateral Sclerosis (ALS) stood out among her fellow finalists.

“We just couldn’t be more ecstatic—for Shreya as well as for the future of all biotech innovation,” said Georgia Bio President and CEO Maria Thacker. “We knew how talented she was when we saw her work, but the fact that our local winner’s unbelievably sophisticated research won the top prize at this advanced level shows you just what we can do in biotech here in Georgia, not to mention how brilliant and innovative Georgia students are.”

Organized by the Biotechnology Institute, the annual competition brings together young innovators from across North America and Germany to compete before an accomplished panel of established biotechnology researchers and academics. The winner walks away with the recognition, advisement, and support of some of the world’s best biotech innovators as well $7,500 in prize money.

Shreya’s research topic focused on the problem of Amyotrophic Lateral Sclerosis (ALS) patients, many of whom rely on Automatic Speech Recognition (ASR) tools such as Google Voice, with voice characteristics that can unfortunately be unreadable to ARS programs. As a result of the condition, the voices of ALS patients can be slow and high pitched, making ARS software interaction problematic. Shreya’s solution was to create a novel voice compensation algorithm that converted an ALS patient’s unique vocal texture into one more easily recognized by the programs.

“Winning the BioGENEius Challenge feels absolutely amazing,” said Shreya Ramesh. “It’s great to know that my project has the potential to change lives and that I’ll have a supportive platform to help me do that. The competition was the  best  experience—I’ve met so many students who are just as passionate as I am about using biotech to change the world!”

Judges of the 2020 International BioGENEius Challenge included BioEd Institute Board Member and past Chair, Jamie Graham, partner at Kilpatrick Townsend & Stockton, to whom Georgia Bio and the Georgia BioEd Institute offer a special thanks.

About the Biotechnology Institute

The Biotechnology Institute is an independent, national nonprofit organization dedicated to education about the present and future impact of biotechnology. Its mission is to engage, excite and educate the public, particularly students and teachers, about biotechnology and its immense potential for solving human health, food and environmental problems. For more information, visit  www.biotechinstitute.org.

About the Georgia BioEd Institute 

The Georgia BioEd Institute is a division of Georgia Bio, a 501(c)(3) nonprofit organization serving the state’s life science industry. The Institute’s mission is to strengthen Georgia’s life sciences workforce pipeline through classroom-to-career initiatives that align with industry needs. Learn more at  www.georgiabioed.org  |  www.gabio.org.

Legal Experts Signal Continued Uncertainty for Life Sciences M&A

By Maria Thacker Goethe • October 22, 2025
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape

Georgia Life Sciences Launches New Podcast Series, Vitals, in Partnership with Cloudcast Media

October 6, 2025
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.

BIO Statement on Most Favored Nation Policies

October 1, 2025
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
MORE POSTS